IDEXX Laboratories, Inc. (IDXX) Position Trimmed by DF Dent & Co. Inc.

DF Dent & Co. Inc. decreased its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 0.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 122,599 shares of the company’s stock after selling 365 shares during the quarter. DF Dent & Co. Inc. owned 0.14% of IDEXX Laboratories worth $19,790,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. D.A. Davidson & CO. lifted its position in IDEXX Laboratories by 160.4% during the second quarter. D.A. Davidson & CO. now owns 625 shares of the company’s stock worth $100,000 after purchasing an additional 385 shares during the period. Sun Life Financial INC raised its stake in IDEXX Laboratories by 9,085.7% during the second quarter. Sun Life Financial INC now owns 643 shares of the company’s stock worth $104,000 after acquiring an additional 636 shares in the last quarter. Capital Advisors Ltd. LLC acquired a new position in IDEXX Laboratories during the second quarter worth about $128,000. Global X Management Co. LLC raised its stake in IDEXX Laboratories by 44.6% during the first quarter. Global X Management Co. LLC now owns 1,047 shares of the company’s stock worth $162,000 after acquiring an additional 323 shares in the last quarter. Finally, Coastline Trust Co acquired a new position in IDEXX Laboratories during the second quarter worth about $202,000. 87.64% of the stock is owned by institutional investors and hedge funds.

Shares of IDEXX Laboratories, Inc. (NASDAQ IDXX) traded down 0.224% on Tuesday, reaching $157.935. The company’s stock had a trading volume of 79,176 shares. The stock has a market cap of $13.78 billion, a P/E ratio of 54.329 and a beta of 0.48. The firm’s 50-day moving average price is $156.04 and its 200-day moving average price is $159.86. IDEXX Laboratories, Inc. has a 12 month low of $102.45 and a 12 month high of $173.01.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Tuesday, August 1st. The company reported $0.95 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.85 by $0.10. The company had revenue of $508.90 million during the quarter, compared to the consensus estimate of $502.44 million. IDEXX Laboratories had a negative return on equity of 473.46% and a net margin of 14.13%. IDEXX Laboratories’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.74 EPS. On average, analysts forecast that IDEXX Laboratories, Inc. will post $3.18 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright and trademark laws. The original version of this piece of content can be read at https://www.com-unik.info/2017/10/10/idexx-laboratories-inc-idxx-position-trimmed-by-df-dent-co-inc.html.

Several research analysts have commented on the company. BidaskClub raised IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a research note on Friday, June 23rd. Stifel Nicolaus reissued a “buy” rating and set a $185.00 target price on shares of IDEXX Laboratories in a research note on Friday, July 14th. Zacks Investment Research raised IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $186.00 target price for the company in a research note on Wednesday, July 19th. CL King raised IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $200.00 target price for the company in a research note on Friday, July 28th. Finally, Canaccord Genuity reissued a “buy” rating and set a $180.00 target price on shares of IDEXX Laboratories in a research note on Tuesday, June 13th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $174.00.

In other news, Director Lawrence D. Kingsley bought 2,000 shares of the company’s stock in a transaction that occurred on Thursday, August 3rd. The stock was bought at an average price of $151.76 per share, for a total transaction of $303,520.00. Following the transaction, the director now directly owns 3,344 shares of the company’s stock, valued at approximately $507,485.44. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Chairman Jonathan W. Ayers sold 13,000 shares of the business’s stock in a transaction that occurred on Monday, August 28th. The stock was sold at an average price of $150.79, for a total value of $1,960,270.00. Following the completion of the sale, the chairman now owns 1,044,034 shares of the company’s stock, valued at approximately $157,429,886.86. The disclosure for this sale can be found here. Insiders sold a total of 151,734 shares of company stock valued at $23,436,626 in the last 90 days. 2.77% of the stock is currently owned by corporate insiders.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

What are top analysts saying about IDEXX Laboratories Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for IDEXX Laboratories Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit